Metagenomi is narrowing its focus to a single lead: advancing its wholly owned MGX-001 genome-editing therapy for hemophilia A...

Cosciens Biopharma has executed a sharp retrenchment: voluntarily delisting from Nasdaq while maintaining its TSX listing, applying for quotation...

Tonix Pharmaceuticals will launch Tonmya, a sublingual 2.8 mg formulation of cyclobenzaprine for fibromyalgia in adults, before the end...

Orchestra BioMed has secured $147.6 million in gross proceeds through a mix of strategic transactions and public and private...

Beyond Air reported a 128% year-over-year revenue increase to $1.8 million for its fiscal second quarter. It secured up...

Mereo BioPharma reported third-quarter 2025 results with cash of $48.7 million and a stated runway into 2027, while confirming...

FibroGen has closed the sale of FibroGen China to AstraZeneca for approximately $220 million and used the proceeds to...

Harrow reported third-quarter 2025 revenue of $71.6 million, up 45% year over year, returning to GAAP profitability with $1.0...

Assembly Biosciences reported positive interim Phase 1b results for ABI-5366 in recurrent genital herpes, showing reductions in HSV-2 shedding,...

Insight Molecular Diagnostics plans to submit its first kitted transplant rejection assay, GraftAssureDx, to the FDA by year-end, holding...